3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
Conditions
Melanoma
16
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Brain Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Gallbladder Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Xanthogranuloma, Juvenile
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Clear Cell
1
Neoplasms, Unknown Primary
1
Microsatellite Unstable Colorectal Cancer
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Inflammatory Breast Neoplasms
1
Histiocytosis, Sinus
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Histiocytic Disorders, Malignant
1
Hematologic Neoplasms
1
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Vemurafenib
2
LY3023414
2
Cyclophosphamide
2
thymoglobulin
1
fludarabine
1
etoposide phosphate
1
cobimetinib
1
Whole-Body Irradiation
1
Tacrolimus
1
Sirolimus
1
Rituximab
1
Pharmacogenomic Variants
1
Mycophenolic Acid
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Histiocytosis, Langerhans-Cell
×
cobimetinib
×
Clear all
NCT04079179
2025-09-18
NACHO-COBI
Baylor College of Medicine
Phase 2
Recruiting
90 enrolled